{"entity":{"type":"insider","cik":"0001779308","url":"/insider/0001779308","json_url":"/insider/0001779308.json","name":"Yale Catriona","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":73,"n_filings":40,"first":"2021-07-19","last":"2025-09-12","span_basis":"filed_date"},"name_variants":[{"name":"Yale Catriona","source":"filing","n_filings":40,"first_seen":"2021-07-19","last_seen":"2025-09-12"}],"transactions":[{"id":5159661,"accession":"0000950170-25-114665","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-114665","line_url":"/filing/0000950170-25-114665#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":659.0,"shares_display":"659","price_per_share":43.02,"price_display":"43.02","price_state":"stated","total_value":28350.18,"total_display":"28,350.18","shares_owned_after":90829.0,"shares_owned_after_display":"90,829","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-11","filed_date":"2025-09-12","scope":"insider"},{"id":4619472,"accession":"0000950170-25-097013","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-097013","line_url":"/filing/0000950170-25-097013#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8658.0,"shares_display":"8,658","price_per_share":52.865,"price_display":"52.86","price_state":"stated","total_value":457705.17,"total_display":"457,705.17","shares_owned_after":92830.0,"shares_owned_after_display":"92,830","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-16","filed_date":"2025-07-18","scope":"insider"},{"id":4619465,"accession":"0000950170-25-097013","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-097013","line_url":"/filing/0000950170-25-097013#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1342.0,"shares_display":"1,342","price_per_share":53.474,"price_display":"53.47","price_state":"stated","total_value":71762.108,"total_display":"71,762.11","shares_owned_after":91488.0,"shares_owned_after_display":"91,488","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-16","filed_date":"2025-07-18","scope":"insider"},{"id":4264522,"accession":"0000950170-25-088636","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-088636","line_url":"/filing/0000950170-25-088636#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1633.0,"shares_display":"1,633","price_per_share":54.84,"price_display":"54.84","price_state":"stated","total_value":89553.72,"total_display":"89,553.72","shares_owned_after":90598.0,"shares_owned_after_display":"90,598","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-18","filed_date":"2025-06-20","scope":"insider"},{"id":4751083,"accession":"0000950170-25-088207","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-088207","line_url":"/filing/0000950170-25-088207#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6210.0,"shares_display":"6,210","price_per_share":53.78,"price_display":"53.78","price_state":"stated","total_value":333973.8,"total_display":"333,973.80","shares_owned_after":96021.0,"shares_owned_after_display":"96,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-20","scope":"insider"},{"id":4751078,"accession":"0000950170-25-088207","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-088207","line_url":"/filing/0000950170-25-088207#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2895.0,"shares_display":"2,895","price_per_share":54.799,"price_display":"54.80","price_state":"stated","total_value":158643.105,"total_display":"158,643.10","shares_owned_after":93126.0,"shares_owned_after_display":"93,126","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-20","scope":"insider"},{"id":4751074,"accession":"0000950170-25-088207","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-088207","line_url":"/filing/0000950170-25-088207#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":895.0,"shares_display":"895","price_per_share":55.519,"price_display":"55.52","price_state":"stated","total_value":49689.505,"total_display":"49,689.50","shares_owned_after":92231.0,"shares_owned_after_display":"92,231","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-16","filed_date":"2025-06-20","scope":"insider"},{"id":4264481,"accession":"0000950170-25-085671","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-085671","line_url":"/filing/0000950170-25-085671#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2803.0,"shares_display":"2,803","price_per_share":53.996,"price_display":"54.00","price_state":"stated","total_value":151350.788,"total_display":"151,350.79","shares_owned_after":92231.0,"shares_owned_after_display":"92,231","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":4462018,"accession":"0000950170-25-074708","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-074708","line_url":"/filing/0000950170-25-074708#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4384.0,"shares_display":"4,384","price_per_share":39.906,"price_display":"39.91","price_state":"stated","total_value":174947.904,"total_display":"174,947.90","shares_owned_after":95034.0,"shares_owned_after_display":"95,034","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-15","filed_date":"2025-05-19","scope":"insider"},{"id":4462015,"accession":"0000950170-25-074708","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-074708","line_url":"/filing/0000950170-25-074708#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2837.0,"shares_display":"2,837","price_per_share":38.199,"price_display":"38.20","price_state":"stated","total_value":108370.563,"total_display":"108,370.56","shares_owned_after":102197.0,"shares_owned_after_display":"102,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-15","filed_date":"2025-05-19","scope":"insider"},{"id":4462010,"accession":"0000950170-25-074708","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-074708","line_url":"/filing/0000950170-25-074708#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2779.0,"shares_display":"2,779","price_per_share":39.46,"price_display":"39.46","price_state":"stated","total_value":109659.34,"total_display":"109,659.34","shares_owned_after":99418.0,"shares_owned_after_display":"99,418","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-15","filed_date":"2025-05-19","scope":"insider"},{"id":4312804,"accession":"0000950170-25-054893","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-054893","line_url":"/filing/0000950170-25-054893#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7873.0,"shares_display":"7,873","price_per_share":37.803,"price_display":"37.80","price_state":"stated","total_value":297623.019,"total_display":"297,623.02","shares_owned_after":96234.0,"shares_owned_after_display":"96,234","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-15","filed_date":"2025-04-16","scope":"insider"},{"id":4312800,"accession":"0000950170-25-054893","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-054893","line_url":"/filing/0000950170-25-054893#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1200.0,"shares_display":"1,200","price_per_share":38.616,"price_display":"38.62","price_state":"stated","total_value":46339.2,"total_display":"46,339.20","shares_owned_after":95034.0,"shares_owned_after_display":"95,034","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-15","filed_date":"2025-04-16","scope":"insider"},{"id":5117479,"accession":"0000950170-25-041458","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-041458","line_url":"/filing/0000950170-25-041458#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8201.0,"shares_display":"8,201","price_per_share":44.697,"price_display":"44.70","price_state":"stated","total_value":366560.097,"total_display":"366,560.10","shares_owned_after":96833.0,"shares_owned_after_display":"96,833","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-17","filed_date":"2025-03-18","scope":"insider"},{"id":5117476,"accession":"0000950170-25-041458","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-041458","line_url":"/filing/0000950170-25-041458#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1799.0,"shares_display":"1,799","price_per_share":45.05,"price_display":"45.05","price_state":"stated","total_value":81044.95,"total_display":"81,044.95","shares_owned_after":95034.0,"shares_owned_after_display":"95,034","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-17","filed_date":"2025-03-18","scope":"insider"},{"id":4712580,"accession":"0000950170-25-039736","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-039736","line_url":"/filing/0000950170-25-039736#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":614.0,"shares_display":"614","price_per_share":44.88,"price_display":"44.88","price_state":"stated","total_value":27556.32,"total_display":"27,556.32","shares_owned_after":95034.0,"shares_owned_after_display":"95,034","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-12","filed_date":"2025-03-14","scope":"insider"},{"id":4945138,"accession":"0000950170-25-024996","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-024996","line_url":"/filing/0000950170-25-024996#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9100.0,"shares_display":"9,100","price_per_share":49.79,"price_display":"49.79","price_state":"stated","total_value":453089.0,"total_display":"453,089.00","shares_owned_after":96548.0,"shares_owned_after_display":"96,548","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-18","filed_date":"2025-02-21","scope":"insider"},{"id":4945133,"accession":"0000950170-25-024996","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-024996","line_url":"/filing/0000950170-25-024996#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":900.0,"shares_display":"900","price_per_share":50.634,"price_display":"50.63","price_state":"stated","total_value":45570.6,"total_display":"45,570.60","shares_owned_after":95648.0,"shares_owned_after_display":"95,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-18","filed_date":"2025-02-21","scope":"insider"},{"id":5030168,"accession":"0000950170-25-011444","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-011444","line_url":"/filing/0000950170-25-011444#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25907.0,"shares_display":"25,907","price_per_share":55.152,"price_display":"55.15","price_state":"stated","total_value":1428822.864,"total_display":"1,428,822.86","shares_owned_after":118815.0,"shares_owned_after_display":"118,815","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-31","scope":"insider"},{"id":5030163,"accession":"0000950170-25-011444","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-011444","line_url":"/filing/0000950170-25-011444#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14467.0,"shares_display":"14,467","price_per_share":55.95,"price_display":"55.95","price_state":"stated","total_value":809428.65,"total_display":"809,428.65","shares_owned_after":104348.0,"shares_owned_after_display":"104,348","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-31","scope":"insider"},{"id":5030155,"accession":"0000950170-25-011444","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-011444","line_url":"/filing/0000950170-25-011444#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8700.0,"shares_display":"8,700","price_per_share":57.007,"price_display":"57.01","price_state":"stated","total_value":495960.9,"total_display":"495,960.90","shares_owned_after":95648.0,"shares_owned_after_display":"95,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-31","scope":"insider"},{"id":4832408,"accession":"0000950170-25-011445","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-25-011445","line_url":"/filing/0000950170-25-011445#line-6","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27340.0,"shares_display":"27,340","price_per_share":57.024,"price_display":"57.02","price_state":"stated","total_value":1559036.16,"total_display":"1,559,036.16","shares_owned_after":95648.0,"shares_owned_after_display":"95,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-31","scope":"insider"},{"id":4832403,"accession":"0000950170-25-011445","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-25-011445","line_url":"/filing/0000950170-25-011445#line-5","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17000.0,"shares_display":"17,000","price_per_share":55.156,"price_display":"55.16","price_state":"stated","total_value":937652.0,"total_display":"937,652.00","shares_owned_after":132238.0,"shares_owned_after_display":"132,238","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-31","scope":"insider"},{"id":4832399,"accession":"0000950170-25-011445","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-011445","line_url":"/filing/0000950170-25-011445#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9250.0,"shares_display":"9,250","price_per_share":55.949,"price_display":"55.95","price_state":"stated","total_value":517528.25,"total_display":"517,528.25","shares_owned_after":122988.0,"shares_owned_after_display":"122,988","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-27","filed_date":"2025-01-31","scope":"insider"},{"id":2652109,"accession":"0000950170-24-138146","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-138146","line_url":"/filing/0000950170-24-138146#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9074.0,"shares_display":"9,074","price_per_share":29.107,"price_display":"29.11","price_state":"stated","total_value":264116.918,"total_display":"264,116.92","shares_owned_after":95648.0,"shares_owned_after_display":"95,648","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-16","filed_date":"2024-12-18","scope":"insider"},{"id":2551749,"accession":"0000950170-24-136019","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-136019","line_url":"/filing/0000950170-24-136019#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2810.0,"shares_display":"2,810","price_per_share":30.79,"price_display":"30.79","price_state":"stated","total_value":86519.9,"total_display":"86,519.90","shares_owned_after":71348.0,"shares_owned_after_display":"71,348","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-10","filed_date":"2024-12-12","scope":"insider"},{"id":2651804,"accession":"0000950170-24-128994","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-128994","line_url":"/filing/0000950170-24-128994#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8761.0,"shares_display":"8,761","price_per_share":27.694,"price_display":"27.69","price_state":"stated","total_value":242627.134,"total_display":"242,627.13","shares_owned_after":74458.0,"shares_owned_after_display":"74,458","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-15","filed_date":"2024-11-19","scope":"insider"},{"id":2651800,"accession":"0000950170-24-128994","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-128994","line_url":"/filing/0000950170-24-128994#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":28.823,"price_display":"28.82","price_state":"stated","total_value":8646.9,"total_display":"8,646.90","shares_owned_after":74158.0,"shares_owned_after_display":"74,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-15","filed_date":"2024-11-19","scope":"insider"},{"id":2903142,"accession":"0000950170-24-124230","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-124230","line_url":"/filing/0000950170-24-124230#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":35.189,"price_display":"35.19","price_state":"stated","total_value":351890.0,"total_display":"351,890.00","shares_owned_after":74158.0,"shares_owned_after_display":"74,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-06","filed_date":"2024-11-08","scope":"insider"},{"id":3022397,"accession":"0000950170-24-120231","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-120231","line_url":"/filing/0000950170-24-120231#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15485.0,"shares_display":"15,485","price_per_share":32.619,"price_display":"32.62","price_state":"stated","total_value":505105.215,"total_display":"505,105.22","shares_owned_after":74158.0,"shares_owned_after_display":"74,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-11-01","filed_date":"2024-11-01","scope":"insider"},{"id":3022385,"accession":"0000950170-24-120231","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-120231","line_url":"/filing/0000950170-24-120231#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4515.0,"shares_display":"4,515","price_per_share":32.526,"price_display":"32.53","price_state":"stated","total_value":146854.89,"total_display":"146,854.89","shares_owned_after":74158.0,"shares_owned_after_display":"74,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-30","filed_date":"2024-11-01","scope":"insider"},{"id":2738572,"accession":"0000950170-24-115138","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-24-115138","line_url":"/filing/0000950170-24-115138#line-5","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14525.0,"shares_display":"14,525","price_per_share":30.496,"price_display":"30.50","price_state":"stated","total_value":442954.4,"total_display":"442,954.40","shares_owned_after":75594.0,"shares_owned_after_display":"75,594","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-16","scope":"insider"},{"id":2738567,"accession":"0000950170-24-115138","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-115138","line_url":"/filing/0000950170-24-115138#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":30.927,"price_display":"30.93","price_state":"stated","total_value":9278.1,"total_display":"9,278.10","shares_owned_after":75294.0,"shares_owned_after_display":"75,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-16","scope":"insider"},{"id":2738560,"accession":"0000950170-24-115138","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-115138","line_url":"/filing/0000950170-24-115138#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6136.0,"shares_display":"6,136","price_per_share":30.029,"price_display":"30.03","price_state":"stated","total_value":184257.944,"total_display":"184,257.94","shares_owned_after":74158.0,"shares_owned_after_display":"74,158","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-14","filed_date":"2024-10-16","scope":"insider"},{"id":2393924,"accession":"0000950170-24-108837","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-108837","line_url":"/filing/0000950170-24-108837#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5500.0,"shares_display":"5,500","price_per_share":27.652,"price_display":"27.65","price_state":"stated","total_value":152086.0,"total_display":"152,086.00","shares_owned_after":75294.0,"shares_owned_after_display":"75,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-20","filed_date":"2024-09-23","scope":"insider"},{"id":2117639,"accession":"0000950170-24-107969","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000950170-24-107969","line_url":"/filing/0000950170-24-107969#line-6","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3871.0,"shares_display":"3,871","price_per_share":27.56,"price_display":"27.56","price_state":"stated","total_value":106684.76,"total_display":"106,684.76","shares_owned_after":75294.0,"shares_owned_after_display":"75,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-18","filed_date":"2024-09-18","scope":"insider"},{"id":2117634,"accession":"0000950170-24-107969","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-107969","line_url":"/filing/0000950170-24-107969#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2037.0,"shares_display":"2,037","price_per_share":27.548,"price_display":"27.55","price_state":"stated","total_value":56115.276,"total_display":"56,115.28","shares_owned_after":75294.0,"shares_owned_after_display":"75,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-17","filed_date":"2024-09-18","scope":"insider"},{"id":2117627,"accession":"0000950170-24-107969","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-107969","line_url":"/filing/0000950170-24-107969#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2485.0,"shares_display":"2,485","price_per_share":27.515,"price_display":"27.52","price_state":"stated","total_value":68374.775,"total_display":"68,374.78","shares_owned_after":75294.0,"shares_owned_after_display":"75,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-16","filed_date":"2024-09-18","scope":"insider"},{"id":3075593,"accession":"0000950170-24-106470","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-106470","line_url":"/filing/0000950170-24-106470#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":637.0,"shares_display":"637","price_per_share":26.18,"price_display":"26.18","price_state":"stated","total_value":16676.66,"total_display":"16,676.66","shares_owned_after":75294.0,"shares_owned_after_display":"75,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-13","scope":"insider"},{"id":2345329,"accession":"0000950170-24-103977","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-103977","line_url":"/filing/0000950170-24-103977#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":949.0,"shares_display":"949","price_per_share":27.614,"price_display":"27.61","price_state":"stated","total_value":26205.686,"total_display":"26,205.69","shares_owned_after":75931.0,"shares_owned_after_display":"75,931","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-03","filed_date":"2024-09-05","scope":"insider"},{"id":2345217,"accession":"0000950170-24-101257","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-24-101257","line_url":"/filing/0000950170-24-101257#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5200.0,"shares_display":"5,200","price_per_share":27.514,"price_display":"27.51","price_state":"stated","total_value":143072.8,"total_display":"143,072.80","shares_owned_after":75931.0,"shares_owned_after_display":"75,931","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-26","filed_date":"2024-08-28","scope":"insider"},{"id":2345210,"accession":"0000950170-24-101257","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-101257","line_url":"/filing/0000950170-24-101257#line-2","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8851.0,"shares_display":"8,851","price_per_share":27.527,"price_display":"27.53","price_state":"stated","total_value":243641.477,"total_display":"243,641.48","shares_owned_after":75931.0,"shares_owned_after_display":"75,931","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-23","filed_date":"2024-08-28","scope":"insider"},{"id":2736651,"accession":"0000950170-24-073190","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-073190","line_url":"/filing/0000950170-24-073190#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2825.0,"shares_display":"2,825","price_per_share":22.641,"price_display":"22.64","price_state":"stated","total_value":63960.825,"total_display":"63,960.82","shares_owned_after":74867.0,"shares_owned_after_display":"74,867","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-11","filed_date":"2024-06-13","scope":"insider"},{"id":2341963,"accession":"0000950170-24-032266","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-032266","line_url":"/filing/0000950170-24-032266#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":723.0,"shares_display":"723","price_per_share":28.33,"price_display":"28.33","price_state":"stated","total_value":20482.59,"total_display":"20,482.59","shares_owned_after":77692.0,"shares_owned_after_display":"77,692","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-15","scope":"insider"},{"id":2825227,"accession":"0000950170-24-027509","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-027509","line_url":"/filing/0000950170-24-027509#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20646.0,"shares_display":"20,646","price_per_share":35.49,"price_display":"35.49","price_state":"stated","total_value":732726.54,"total_display":"732,726.54","shares_owned_after":78415.0,"shares_owned_after_display":"78,415","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-04","filed_date":"2024-03-06","scope":"insider"},{"id":8108851,"accession":"0000950170-23-071250","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-071250","line_url":"/filing/0000950170-23-071250#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":597.0,"shares_display":"597","price_per_share":20.76,"price_display":"20.76","price_state":"stated","total_value":12393.72,"total_display":"12,393.72","shares_owned_after":77910.0,"shares_owned_after_display":"77,910","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-14","filed_date":"2023-12-18","scope":"insider"},{"id":8724282,"accession":"0000950170-23-049765","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-23-049765","line_url":"/filing/0000950170-23-049765#line-4","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2800.0,"shares_display":"2,800","price_per_share":47.8461,"price_display":"47.85","price_state":"stated","total_value":133969.08,"total_display":"133,969.08","shares_owned_after":48210.0,"shares_owned_after_display":"48,210","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-21","filed_date":"2023-09-25","scope":"insider"},{"id":8724280,"accession":"0000950170-23-049765","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-23-049765","line_url":"/filing/0000950170-23-049765#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2200.0,"shares_display":"2,200","price_per_share":48.3577,"price_display":"48.36","price_state":"stated","total_value":106386.94,"total_display":"106,386.94","shares_owned_after":46010.0,"shares_owned_after_display":"46,010","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-21","filed_date":"2023-09-25","scope":"insider"},{"id":8724274,"accession":"0000950170-23-049765","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-049765","line_url":"/filing/0000950170-23-049765#line-1","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":617.0,"shares_display":"617","price_per_share":50.34,"price_display":"50.34","price_state":"stated","total_value":31059.78,"total_display":"31,059.78","shares_owned_after":46010.0,"shares_owned_after_display":"46,010","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-13","filed_date":"2023-09-25","scope":"insider"},{"id":7963315,"accession":"0000950170-23-045549","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-23-045549","line_url":"/filing/0000950170-23-045549#line-3","is_derivative":false,"issuer_cik":"0001744659","issuer_name":"Akero Therapeutics, Inc.","issuer_ticker":"AKRO","issuer_name_source":null,"issuer_url":"/issuer/0001744659","owner_cik":"0001779308","owner_name":"Yale Catriona","owner_url":"/insider/0001779308","role":"Officer (Chief Development Officer)","officer_title":"Chief Development Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5245.0,"shares_display":"5,245","price_per_share":49.9248,"price_display":"49.92","price_state":"stated","total_value":261855.576,"total_display":"261,855.58","shares_owned_after":47127.0,"shares_owned_after_display":"47,127","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-28","filed_date":"2023-08-30","scope":"insider"}],"next_cursor":"2023-08-28|7963315","ledger_fault":false,"count":{"value":73,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":73,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":73},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Officer (Chief Development Officer)","n_filings":40,"first_seen":"2021-07-19","last_seen":"2025-09-12"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001779308","retrieved_at":"2026-08-21T18:00:20+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}